START TYPING AND PRESS ENTER TO SEARCH

    Receive this Monthly Publication in your Inbox

    Never miss the latest in Healthcare Performance Insider by subscribing HERE!

    @Copyright 2019 - Healthcare Performance Insider a publication from Accumen, Inc

    Where should we send your newsletter?

    Privacy Policy: We hate spam and promise to keep your email address safe

    Brian Morgan

    As we work to safely reopen our economy, continued and ongoing COVID-19 testing will be a key component in preventing another uncontrolled outbreak and minimizing the number of “hot spots.” The clinical laboratory industry has worked hard to increase capacity for testing to meet the new demands.  In order to open schools, universities, other public events and gatherings safely, it will require connecting laboratories with available testing and the various tracing, proof-of-testing apps and solutions.

    To maintain the reliability of those solutions, a “chain-of-evidence” model that electronically delivers verified patient results to the solution will be necessary.  This will be key in helping to combat false results that could come from a variety of sources, including patients self-diagnosing themselves as positive, hiding results because they don’t “feel sick” and don’t want to miss that concert event, or even bad actors trying to falsely trigger proximity contact tracing apps in a crowded space.  Since there are no national or even regional platforms emerging for contact tracing or proof-of-testing, a clinical lab performing COVID-19 testing will need to be vendor neutral and be able to scale rapidly.  A partnership with a clinical data exchange (CDE) engine allows a laboratory to have this neutrality and scalability available.

    In addition to meeting the electronic order requirements of the clinical lab, a strong CDE partner can quickly and efficiently work with the variety of apps and solutions that are emerging.  These vendors have varying data requirements, varying levels of experience with clinical data, and a lab’s CDE partner should be one that can navigate that without causing the lab any extra work.  The CDE should have the ability to manage the complexity of patient identification, to ensure the right results are attached to the right person.  When bringing the right tools, a CDE partner brings tremendous value to a laboratory, for COVID-19 and beyond.

    Brian Morgan

    Brian Morgan

    Vice President and General Manager of Clinical Data Exchange, Halfpenny Technologies

    I always tell our team to never forget the challenges that our customers are facing in trying to accomplish their mission – and our job is to help them. And at the end of the day, the reward at seeing how we can impact their ability to do their job quicker, easier and more effectively makes the challenge well worth it.

    – Randy Campbell, Chief Technology Officer, Interlace Health,

    Healthcare Industry Webinars

    Interesting Fact

    Since the coronavirus outbreak, the number of Telehealth visits rose from 14% to 57% and for those with chronic illness the number has increased by 77%. 

    Announcements

    • Join Accumen, The Society for the Advancement of Patient Blood Management, and AABB are co-hosting a webinar titled, Let's Not Go Back to Normal, The Essential Role of Patient Blood Management. 
    • Accumen, Modern Healthcare and telehealth experts, Dr. Eric Wallace, MD, UAB Medical Director and Dr. Darrel Weaver, Vice President BlueCross BlueShield of Alabama hosting a timely webinar on April 22nd.